Trial Details

Not Recruiting
Basic Information
Clinical ID c2644
Identifier EUCTR2019-002070-31-DK
Trial Title Adherence of a 1.600 mg single tablet 5-ASA treatment of Ulcerative colitis (EASI-trial)
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Ulcerative colitis (UC) belongs to the group of inflammatory bowel diseases. The disease course is unpredictable and characterised by chronic inflammation of the colonic mucosa, where acute attacks are followed by periods of remission. Development of UC is characterized by a dysregulated immune response and barrier dysfunction caused by genetic susceptibility and environmental triggers. UC only involves the colon, starting in the rectum and extending to proximal segments of the colon.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Interventions Trade Name: ASACOL Pharmaceutical Form: Tablet INN or Proposed INN: MESALAZINE CAS Number: 89-57-6 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1600-4800
Participant Information
Sponsor Copenhagen University Hospital Hvidovre
City -
Country/Region Denmark
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement -
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE4
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -